609 related articles for article (PubMed ID: 31540045)
1. Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges.
Noman MZ; Hasmim M; Lequeux A; Xiao M; Duhem C; Chouaib S; Berchem G; Janji B
Cells; 2019 Sep; 8(9):. PubMed ID: 31540045
[TBL] [Abstract][Full Text] [Related]
2. Targeting Autophagy in the Tumor Microenvironment: New Challenges and Opportunities for Regulating Tumor Immunity.
Janji B; Berchem G; Chouaib S
Front Immunol; 2018; 9():887. PubMed ID: 29922284
[TBL] [Abstract][Full Text] [Related]
3. Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer.
Chouaib S; Noman MZ; Kosmatopoulos K; Curran MA
Oncogene; 2017 Jan; 36(4):439-445. PubMed ID: 27345407
[TBL] [Abstract][Full Text] [Related]
4. Targeting hypoxia and hypoxia-inducible factor-1 in the tumor microenvironment for optimal cancer immunotherapy.
Kheshtchin N; Hadjati J
J Cell Physiol; 2022 Feb; 237(2):1285-1298. PubMed ID: 34796969
[TBL] [Abstract][Full Text] [Related]
5. Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy.
Wang B; Zhao Q; Zhang Y; Liu Z; Zheng Z; Liu S; Meng L; Xin Y; Jiang X
J Exp Clin Cancer Res; 2021 Jan; 40(1):24. PubMed ID: 33422072
[TBL] [Abstract][Full Text] [Related]
6. Directing Hypoxic Tumor Microenvironment and HIF to Illuminate Cancer Immunotherapy's Existing Prospects and Challenges in Drug Targets.
Ray SK; Mukherjee S
Curr Drug Targets; 2022; 23(5):471-485. PubMed ID: 35021970
[TBL] [Abstract][Full Text] [Related]
7. Microenvironmental hypoxia orchestrating the cell stroma cross talk, tumor progression and antitumor response.
Noman MZ; Messai Y; Carré T; Akalay I; Méron M; Janji B; Hasmim M; Chouaib S
Crit Rev Immunol; 2011; 31(5):357-77. PubMed ID: 22142164
[TBL] [Abstract][Full Text] [Related]
8. Tumor Hypoxia: A Key Determinant of Microenvironment Hostility and a Major Checkpoint during the Antitumor Response.
Francis A; Venkatesh GH; Zaarour RF; Zeinelabdin NA; Nawafleh HH; Prasad P; Buart S; Terry S; Chouaib S
Crit Rev Immunol; 2018; 38(6):505-524. PubMed ID: 31002604
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.
Rohwer N; Cramer T
Drug Resist Updat; 2011 Jun; 14(3):191-201. PubMed ID: 21466972
[TBL] [Abstract][Full Text] [Related]
10. The Promise of Targeting Hypoxia to Improve Cancer Immunotherapy: Mirage or Reality?
Janji B; Chouaib S
Front Immunol; 2022; 13():880810. PubMed ID: 35795658
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-induced autophagy: a new player in cancer immunotherapy?
Noman MZ; Janji B; Berchem G; Mami-Chouaib F; Chouaib S
Autophagy; 2012 Apr; 8(4):704-6. PubMed ID: 22441015
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-modulatory nanomaterials to relieve tumor hypoxic microenvironment and enhance immunotherapy: Where do we stand?
Yuan CS; Deng ZW; Qin D; Mu YZ; Chen XG; Liu Y
Acta Biomater; 2021 Apr; 125():1-28. PubMed ID: 33639310
[TBL] [Abstract][Full Text] [Related]
13. Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy.
Abou Khouzam R; Goutham HV; Zaarour RF; Chamseddine AN; Francis A; Buart S; Terry S; Chouaib S
Semin Cancer Biol; 2020 Oct; 65():140-154. PubMed ID: 31927131
[TBL] [Abstract][Full Text] [Related]
14. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.
Palazón A; Martínez-Forero I; Teijeira A; Morales-Kastresana A; Alfaro C; Sanmamed MF; Perez-Gracia JL; Peñuelas I; Hervás-Stubbs S; Rouzaut A; de Landázuri MO; Jure-Kunkel M; Aragonés J; Melero I
Cancer Discov; 2012 Jul; 2(7):608-23. PubMed ID: 22719018
[TBL] [Abstract][Full Text] [Related]
15. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy.
Meijer TW; Kaanders JH; Span PN; Bussink J
Clin Cancer Res; 2012 Oct; 18(20):5585-94. PubMed ID: 23071360
[TBL] [Abstract][Full Text] [Related]
16. Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy.
Bader JE; Voss K; Rathmell JC
Mol Cell; 2020 Jun; 78(6):1019-1033. PubMed ID: 32559423
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia and cancer cell metabolism.
Huang D; Li C; Zhang H
Acta Biochim Biophys Sin (Shanghai); 2014 Mar; 46(3):214-9. PubMed ID: 24389642
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia as a potential inducer of immune tolerance, tumor plasticity and a driver of tumor mutational burden: Impact on cancer immunotherapy.
Abou Khouzam R; Janji B; Thiery J; Zaarour RF; Chamseddine AN; Mayr H; Savagner P; Kieda C; Gad S; Buart S; Lehn JM; Limani P; Chouaib S
Semin Cancer Biol; 2023 Dec; 97():104-123. PubMed ID: 38029865
[TBL] [Abstract][Full Text] [Related]
19. Recent Advances In Developing Novel Anti-Cancer Drugs Targeting Tumor Hypoxic and Acidic Microenvironments.
Li W; Sun X
Recent Pat Anticancer Drug Discov; 2018; 13(4):455-468. PubMed ID: 30173649
[TBL] [Abstract][Full Text] [Related]
20. Nanotherapeutic approaches targeting angiogenesis and immune dysfunction in tumor microenvironment.
Hameed S; Bhattarai P; Dai Z
Sci China Life Sci; 2018 Apr; 61(4):380-391. PubMed ID: 29607461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
